[DE] GUANIDINDERIVATE<br/>[EN] GUANIDINE DERIVATIVES<br/>[FR] DERIVES DE GUANIDINE
申请人:ACTELION PHARMACEUTICALS LTD
公开号:WO2005023781A1
公开(公告)日:2005-03-17
Guanidinderivate der allgemeinen Formel (I) sowie Hydrate oder Solvate davon, als Neuropeptid FF Rezeptor-Antagonisten zur Behandlung von Schmerz und Hyperalgesie, von Entzugserscheinungen bei Alkohol-, Psychopharmaka- und Nicotinabhängigkeit und zur Verhinderung oder Aufhebung dieser Abhängigkeiten, zur Regulierung der Insulin-Freisetzung, der Nahrungsaufnahme, von Gedächtnisfunktionen, des Blutdrucks, des Elektrolyt- und Energiehaushaltes, und zur Behandlung von Harninkontinenz.
The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinence.
Mechanistic aspect of ring transformations in the reaction of 5-nitro-4-pyrimidinone with acetophenone derivatives and cycloalkanones depending on the electron density/ring size of the ketone
idinone undergoes two kinds of nucleophilic type ring transformations upon treatment with cycloalkanones in the presence of ammonium acetate, which affords 4,5-disubstituted pyrimidines and 5,6-disubstituted 3-nitro-2-pyridones. In order to improve the synthetic utility of this reaction, it is necessary to control the regioselectivity of these ring transformations. In the present work, we performed
3-Methyl-5-nitropyrimidin-4(3H)-one reacts with
ketones in the presence of ammonium salts to afford disubstituted
pyrimidines and disubstituted 3-nitro-2-pyridones in a novel ring
transformation reaction; nitropyrimidinone behaves as an activated
diformylamine in the former case, and as a synthetic equivalent of
α-nitroformylacetic acid in the latter case.